Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Autoimmune Disorders

Free Subscription Articles published in Kidney Int Retrieve available abstracts of 147 articles: HTML format

Single Articles

June 2024
1. TANG J, Xiao Z, Liu L, Li X, et al
   Renal artery microaneurysms in antineutrophil cytoplasmic antibody-associated vasculitis.
   Kidney Int. 2024;105:1326.
   PubMed    
   
   
   
2. ROVIRA J, Arana C, Garcia-Busquets A, Gille I, et al
   Chimeric autoantibody receptor cell therapy for the treatment of membranous nephropathy.
   Kidney Int. 2024;105:1320.
   PubMed    
   
   
   
3. HAAS M
   Podocyte injury as a potential therapeutic target in IgA nephropathy: should pathology guide us?
   Kidney Int. 2024;105:1165-1167.
   PubMed     Abstract available
   
   
   
4. UEDA Y, Nakazawa D, Nishio S, Shiratori-Aso S, et al
   Transcription factor Nrf2 activation regulates NETosis, endothelial injury, and kidney disease in myeloperoxidase-positive antineutrophil cytoplasmic antibody-associated vasculitis.
   Kidney Int. 2024;105:1291-1305.
   PubMed     Abstract available
   
   
   May 2024
5. ABBAD L, Detrait M, Kavvadas P, Bergonnier D, et al
   Signaling through cAMP-Epac1 induces metabolic reprogramming to protect podocytes in glomerulonephritis.
   Kidney Int. 2024 May 29:S0085-2538(24)00380-6. doi: 10.1016/j.kint.2024.
   PubMed     Abstract available
   
   
   April 2024
6. NARAYANAN R, Sivadas S, Kurien AA
   NELL-1 associated membranous nephropathy linked to skin fairness cream use- insights from an Indian case series.
   Kidney Int. 2024 Apr 12:S0085-2538(24)00263-1. doi: 10.1016/j.kint.2024.
   PubMed    
   
   
   
7. SELVASKANDAN H, Barratt J
   Charting new frontiers in IgA nephropathy: a paradigm shift toward precision medicine and early intervention?
   Kidney Int. 2024;105:659-661.
   PubMed     Abstract available
   
   
   March 2024
8. BELLUR SS, Troyanov S, Vorobyeva O, Coppo R, et al
   Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in IgA nephropathy.
   Kidney Int. 2024 Mar 28:S0085-2538(24)00235-7. doi: 10.1016/j.kint.2024.
   PubMed     Abstract available
   
   
   
9. LAFAYETTE R, Barbour S, Israni R, Wei X, et al
   A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
   Kidney Int. 2024 Mar 27:S0085-2538(24)00236-9. doi: 10.1016/j.kint.2024.
   PubMed     Abstract available
   
   
   
10. WANG H, Zuiani J, Coates Ao PT, Xia Y, et al
    Reconstructing the interface between the human intestine and immune system: potential to advance mechanistic studies in IgA nephropathy.
    Kidney Int. 2024;105:423-426.
    PubMed    
    
    
    
11. FLOEGE J, Jayne DRW, Sanders JF, Tesar V, et al
    Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis.
    Kidney Int. 2024;105:447-449.
    PubMed     Abstract available
    
    
    
12. 
    KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
    Kidney Int. 2024;105.
    PubMed    
    
    
    February 2024
13. VOINESCU CD, Mozere M, Genovese G, Downie ML, et al
    A Neanderthal haplotype introgressed into the human genome confers protection against membranous nephropathy.
    Kidney Int. 2024 Feb 14:S0085-2538(24)00073-5. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
14. TANIGUCHI T, Hiwa R, Morinobu A
    Pitfalls in evaluating the impact of persistent hematuria after induction therapy on kidney prognosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
    Kidney Int. 2024;105:391-392.
    PubMed    
    
    
    
15. WIMBURY D, Muto M, Bhachu JS, Scionti K, et al
    Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial.
    Kidney Int. 2024;105:381-388.
    PubMed    
    
    
    
16. SEIFERT L, Riecken K, Zahner G, Hambach J, et al
    An antigen-specific chimeric autoantibody receptor NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells.
    Kidney Int. 2024 Feb 1:S0085-2538(24)00080-2. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    January 2024
17. WANG H, Shen M, Ma Y, Lan L, et al
    Novel mitophagy inducer alleviates lupus nephritis by reducing myeloid cell activation and autoantigen presentation.
    Kidney Int. 2024 Jan 29:S0085-2538(24)00064-4. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
18. ROVIN BH, Ayoub IM, Chan TM, Liu ZH, et al
    Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis.
    Kidney Int. 2024;105:31-34.
    PubMed     Abstract available
    
    
    
19. FLOEGE J
    A new alternative: inhibiting complement activation in patients with IgA nephropathy.
    Kidney Int. 2024;105:28-30.
    PubMed     Abstract available
    
    
    
20. 
    KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.
    Kidney Int. 2024;105.
    PubMed    
    
    
    
21. LUCIENTES-CONTINENTE L, Fernandez-Juarez G, Marquez-Tirado B, Jimenez-Villegas L, et al
    Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
    Kidney Int. 2024;105:177-188.
    PubMed     Abstract available
    
    
    
22. DYLEWSKI JF, Haddad G, Blaine J
    Exploiting the neonatal crystallizable fragment receptor to treat kidney disease.
    Kidney Int. 2024;105:54-64.
    PubMed     Abstract available
    
    
    December 2023
23. RIVEDAL M, Mikkelsen H, Marti HP, Liu L, et al
    Glomerular transcriptomics predicts long term outcome and identifies therapeutic strategies for patients with assumed benign IgA nephropathy.
    Kidney Int. 2023 Dec 26:S0085-2538(23)00920-1. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
24. KISTLER AD, Salant DJ
    Complement Activation and Effector Pathways in Membranous Nephropathy.
    Kidney Int. 2023 Dec 21:S0085-2538(23)00868-2. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
25. ROBSON KJ
    Laminin-521: a novel target for pathogenic autoantibodies in anti-glomerular basement membrane disease.
    Kidney Int. 2023;104:1054-1056.
    PubMed     Abstract available
    
    
    November 2023
26. BECK LH JR
    The latest model has just arrived! A new experimental mouse model of PLA2R1-associated membranous nephropathy.
    Kidney Int. 2023;104:878-880.
    PubMed     Abstract available
    
    
    October 2023
27. ZHANG H, Rizk DV, Perkovic V, Maes B, et al
    Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
    Kidney Int. 2023 Oct 30:S0085-2538(23)00754-8. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
28. KIM M, Kim SS, Choi HI, Choi HS, et al
    Cryofibrinogen-associated membranoproliferative glomerulonephritis.
    Kidney Int. 2023;104:860.
    PubMed    
    
    
    
29. TANIGUCHI T, Hiwa R, Morinobu A
    The conclusion that myeloperoxidase inhibition is not protective against anti-neutrophil cytoplasmic autoantibody-associated vasculitis is premature.
    Kidney Int. 2023;104:856.
    PubMed    
    
    
    September 2023
30. SETHI S, Beck LH Jr, Glassock RJ, Haas M, et al
    Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification.
    Kidney Int. 2023 Sep 6:S0085-2538(23)00490-8. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    August 2023
31. LEE M, Suzuki H, Ogiwara K, Aoki R, et al
    The nucleotide-sensing Toll-Like Receptor 9/Toll-Like Receptor 7 system is a potential therapeutic target for IgA nephropathy.
    Kidney Int. 2023 Aug 28:S0085-2538(23)00609-9. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
32. KUANG H, Shen CR, Jia XY, Tan M, et al
    Autoantibodies against Laminin-521 are Pathogenic in Anti-glomerular Basement Membrane Disease.
    Kidney Int. 2023 Aug 18:S0085-2538(23)00561-6. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
33. TOMAS NM, Schnarre A, Dehde S, Lucas R, et al
    A novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy.
    Kidney Int. 2023 Aug 18:S0085-2538(23)00562-8. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
34. CASTER DJ, Powell DW
    One antigen closer to understanding membranous nephropathy.
    Kidney Int. 2023;104:242-244.
    PubMed     Abstract available
    
    
    July 2023
35. WANG YN, Gan T, Qu S, Xu LL, et al
    MTMR3 risk alleles enhance Toll Like Receptor 9-induced IgA immunity in IgA nephropathy.
    Kidney Int. 2023 Jul 4:S0085-2538(23)00472-6. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
36. LU C, Kitching AR
    RORing toward immunoregulation in glomerulonephritis?
    Kidney Int. 2023;104:28-31.
    PubMed     Abstract available
    
    
    June 2023
37. BENICHOU N, Charles P, Terrier B, Jones RB, et al
    Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis.
    Kidney Int. 2023;103:1144-1155.
    PubMed     Abstract available
    
    
    
38. ISNARD P, Tang E, Mroue A, Letavernier E, et al
    The Case | Crescentic glomerulonephritis in a kidney transplant recipient.
    Kidney Int. 2023;103:1205-1206.
    PubMed    
    
    
    May 2023
39. BARRATT J, Lafayette RA, Zhang H, Tesar V, et al
    IgA Nephropathy: the Lectin Pathway and Implications for Targeted Therapy.
    Kidney Int. 2023 May 30:S0085-2538(23)00395-2. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
40. GLEESON PJ, Sokol H, Monteiro RC
    CARD9, VAV3, and infection risk in IgA nephropathy.
    Kidney Int. 2023;103:996-997.
    PubMed    
    
    
    
41. GANDOLFINI I, Alibrandi S, Gentile M, Russo LS, et al
    Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation.
    Kidney Int. 2023;103:995-996.
    PubMed    
    
    
    
42. GUTIERREZ E, Caravaca-Fontan F, Sevillano A
    Is the NefIgArd trial a paradigm shift in the treatment of IgA nephropathy?
    Kidney Int. 2023;103:994.
    PubMed    
    
    
    
43. JACKSON SW, Rovin BH
    Resolving a paradox between mouse and man: a genetic link between TLR7 and the pathogenesis of human lupus nephritis.
    Kidney Int. 2023;103:824-826.
    PubMed    
    
    
    
44. BAJEMA IM, Balow JE, Haas M, Jayne D, et al
    Update on scoring and providing evidence basis for assessing pathology in lupus nephritis.
    Kidney Int. 2023;103:813-816.
    PubMed    
    
    
    
45. SIM JCJ, Patel P, Chacko B
    The Case | Pulmonary renal syndrome.
    Kidney Int. 2023;103:1001-1002.
    PubMed    
    
    
    
46. SHARMA RK, Yoosuf N, Afonso M, Scheffschick A, et al
    Identification of proteinase 3 autoreactive CD4(+)T cells and their T-cell receptor repertoires in antineutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2023;103:973-985.
    PubMed     Abstract available
    
    
    April 2023
47. SETHI S, Casal Moura M, Madden B, Debiec H, et al
    Proprotein Convertase Subtilisin/Kexin Type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use.
    Kidney Int. 2023 Apr 27:S0085-2538(23)00312-5. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
48. YOO EJ, Oh KH, Piao H, Kang HJ, et al
    Macrophage transcription factor TonEBP promotes systemic lupus erythematosus and kidney injury via damage-induced signaling pathways.
    Kidney Int. 2023 Apr 21:S0085-2538(23)00261-2. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
49. AENDEKERK JP, Ysermans R, Busch MH, Theunissen ROMFIH, et al
    Assessment of longitudinal serum neutrophil extracellular trap-inducing activity in anti-neutrophil cytoplasmic antibody-associated vasculitis and glomerulonephritis in a prospective cohort using a novel bio-impedance technique.
    Kidney Int. 2023 Apr 21:S0085-2538(23)00260-0. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
50. ROVIN BH
    IgA nephropathy and glucocorticoids-a limbo dance?
    Kidney Int. 2023;103:673.
    PubMed    
    
    
    
51. CHEUNG CK, Barratt J
    First do no harm: systemic glucocorticoids should not be used for the treatment of progressive IgA nephropathy.
    Kidney Int. 2023;103:669-673.
    PubMed    
    
    
    
52. ZHANG YM, Lv JC, Wong MG, Zhang H, et al
    Glucocorticoids for IgA nephropathy-pro.
    Kidney Int. 2023;103:666-669.
    PubMed    
    
    
    March 2023
53. HERRNSTADT GR, Niehus CB, Ramcke T, Hagenstein J, et al
    The CCR6/CCL20 Axis Expands RORgammat(+) Tregs to Protect from Glomerulonephritis.
    Kidney Int. 2023 Mar 14:S0085-2538(23)00164-3. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
54. WANG W, Su CT, Lin WC, Huang CK, et al
    Perirenal IgG4-related disease.
    Kidney Int. 2023;103:642.
    PubMed    
    
    
    
55. FRIBOURG M, Cravedi P
    Anti-PLA2R1 antibodies in membranous nephropathy: do we have the smoking gun?
    Kidney Int. 2023;103:639.
    PubMed    
    
    
    
56. SETHI S, Madden B
    Mapping antigens of membranous nephropathy: almost there.
    Kidney Int. 2023;103:469-472.
    PubMed     Abstract available
    
    
    
57. HOXHA E
    T-cell epitopes of PLA2R1 in membranous nephropathy: another step toward antigen-based immunotherapies.
    Kidney Int. 2023;103:466-469.
    PubMed     Abstract available
    
    
    February 2023
58. KAUR P, Prabhahar A, Kumar A, Pal D, et al
    Complementary medicine and phospholipase A2 receptor (PLA2R)-related membranous nephropathy-fortuitous or causal?
    Kidney Int. 2023;103:425-427.
    PubMed    
    
    
    
59. CAZA TN, Larsen CP
    False-positive anti-PLA2R ELISA testing in patients with diabetes mellitus.
    Kidney Int. 2023;103:425.
    PubMed    
    
    
    
60. COPPO R
    A disease-modifying approach to the treatment of IgA nephropathy targeting mucosal IgA synthesis and beyond.
    Kidney Int. 2023;103:258-261.
    PubMed     Abstract available
    
    
    
61. BIHL F, Lambeau G
    Toward a bona fide animal model of PLA2R1-associated membranous nephropathy: one step forward.
    Kidney Int. 2023;103:251-253.
    PubMed     Abstract available
    
    
    
62. SI M, Li L, Fang M, Ye Z, et al
    Anomalous kinetics of galactose-deficient IgA incurring nephropathy revealed by cross-scale optical imaging.
    Kidney Int. 2023;103:320-330.
    PubMed     Abstract available
    
    
    
63. BARRATT J, Lafayette R, Kristensen J, Stone A, et al
    Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
    Kidney Int. 2023;103:391-402.
    PubMed     Abstract available
    
    
    January 2023
64. CAZA TN, Storey A, Hassen SI, Herzog C, et al
    Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry.
    Kidney Int. 2023 Jan 10:S0085-2538(23)00005-4. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
65. FLOREZ-BARROS F, Bearder S, Kull B, Freeman A, et al
    Myeloid expression of the anti-apoptotic protein Mcl1 is required in anti-myeloperoxidase vasculitis but myeloperoxidase inhibition is not protective.
    Kidney Int. 2023;103:134-143.
    PubMed     Abstract available
    
    
    December 2022
66. ZHANG XD, Lin CX, Cui Z, Gu QH, et al
    Mapping the T cell epitopes of the M-type transmembrane phospholipase A2 receptor in primary membranous nephropathy.
    Kidney Int. 2022 Dec 19:S0085-2538(22)01039-0. doi: 10.1016/j.kint.2022.
    PubMed     Abstract available
    
    
    
67. CHEN A, Lee K, He JC
    Treating crescentic glomerulonephritis by targeting macrophages.
    Kidney Int. 2022;102:1212-1214.
    PubMed     Abstract available
    
    
    November 2022
68. BARTON M
    Endothelium and endothelin: regulators of arterial stiffness and fibrinolysis in ANCA-associated vasculitis.
    Kidney Int. 2022;102:963-966.
    PubMed     Abstract available
    
    
    
69. FARRAH TE, Melville V, Czopek A, Fok H, et al
    Arterial stiffness, endothelial dysfunction and impaired fibrinolysis are pathogenic mechanisms contributing to cardiovascular risk in ANCA-associated vasculitis.
    Kidney Int. 2022;102:1115-1126.
    PubMed     Abstract available
    
    
    
70. SHIM JS, Kim EJ, Lee LE, Kim JY, et al
    The oxidative phosphorylation inhibitor IM156 suppresses B-cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus.
    Kidney Int. 2022 Nov 1. pii: S0085-2538(22)00913.
    PubMed     Abstract available
    
    
    October 2022
71. HOXHA E, Reinhard L, Castedello T, Becker JU, et al
    False positivity for PLA2R1-antibody measured by ELISA in a nephrotic patient with no membranous nephropathy.
    Kidney Int. 2022 Oct 5. pii: S0085-2538(22)00807.
    PubMed    
    
    
    
72. JACKSON SW, Alpers CE
    Lupus nephritis transcriptomics across space and time.
    Kidney Int. 2022;102:694-696.
    PubMed     Abstract available
    
    
    September 2022
73. TOMAS NM, Dehde S, Meyer-Schwesinger C, Huang M, et al
    Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice.
    Kidney Int. 2022 Sep 30. pii: S0085-2538(22)00804.
    PubMed     Abstract available
    
    
    
74. DIEBOLD M, Locher E, Boide P, Enzler-Tschudy A, et al
    Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased.
    Kidney Int. 2022 Sep 9. pii: S0085-2538(22)00697.
    PubMed     Abstract available
    
    
    
75. KURIEN AA, Jansi Prema KS, Walker P, Caza T, et al
    Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy.
    Kidney Int. 2022 Sep 9. pii: S0085-2538(22)00712.
    PubMed    
    
    
    
76. LUO C, Ouyang Y, Shi S, Li G, et al
    Particulate matter of air pollution may increase risk of kidney failure in IgA nephropathy.
    Kidney Int. 2022 Sep 7. pii: S0085-2538(22)00696.
    PubMed     Abstract available
    
    
    August 2022
77. TODA E, Sawada A, Takeuchi K, Wakamatsu K, et al
    Inhibition of the chemokine signal regulator FROUNT by disulfiram ameliorates crescentic glomerulonephritis.
    Kidney Int. 2022 Aug 29. pii: S0085-2538(22)00687.
    PubMed     Abstract available
    
    
    
78. CHANG JC, Weiss PF, Xiao R, Atkinson MA, et al
    Use of renin angiotensin aldosterone system inhibitors in children with lupus and time to glucocorticoid discontinuation.
    Kidney Int. 2022;102:395-404.
    PubMed     Abstract available
    
    
    
79. YU XJ, Wang SX
    Recognizing the true face of noninfectious cryoglobulinemic glomerulonephritis.
    Kidney Int. 2022;102:238-241.
    PubMed     Abstract available
    
    
    July 2022
80. FLOEGE J, Wied S, Rauen T
    Assessing prognosis in IgA nephropathy.
    Kidney Int. 2022;102:22-24.
    PubMed     Abstract available
    
    
    
81. PARIKH SV, Malvar A, Song H, Shapiro J, et al
    Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis.
    Kidney Int. 2022 Jul 1. pii: S0085-2538(22)00512.
    PubMed     Abstract available
    
    
    June 2022
82. MISRA DP, Agarwal V
    Management of refractory lupus nephritis: rationale to consider tacrolimus.
    Kidney Int. 2022;101:1293.
    PubMed    
    
    
    
83. LODI L, Mastrolia MV, Bello F, Rossi GM, et al
    Type I interferon-related kidney disorders.
    Kidney Int. 2022;101:1142-1159.
    PubMed     Abstract available
    
    
    May 2022
84. MONTAGUD-MARRAHI E, Cuadrado-Payan E, Hermida E, Cacho J, et al
    Preemptive simultaneous pancreas kidney transplantation has survival benefit to patient.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00385.
    PubMed     Abstract available
    
    
    
85. JAVAUGUE V, Valeri AM, Sathick IJ, Said SM, et al
    The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis.
    Kidney Int. 2022 May 2. pii: S0085-2538(22)00349.
    PubMed     Abstract available
    
    
    April 2022
86. BARBOUR SJ, Coppo R, Zhang H, Liu ZH, et al
    Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.
    Kidney Int. 2022 Apr 29. pii: S0085-2538(22)00342.
    PubMed     Abstract available
    
    
    March 2022
87. VINK CH, van Cranenbroek B, van der Heijden JW, Koenen HPJM, et al
    Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy.
    Kidney Int. 2022;101:646-647.
    PubMed    
    
    
    
88. CHENG L, Gou SJ
    Whether the addition of high-dosage methylprednisolone to plasma exchange was more effective than plasma exchange in the treatment for severe antineutrophil cytoplasmic antibody-associated vasculitis?
    Kidney Int. 2022;101:647-648.
    PubMed    
    
    
    February 2022
89. KANT S, Azar A, Geetha D
    Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2022;101:414-415.
    PubMed    
    
    
    
90. CAZA TN, Larsen CP
    Lipoic acid in neural epidermal growth factor-like 1-associated membranous nephropathy: more than a coincidence?
    Kidney Int. 2022;101:418-419.
    PubMed    
    
    
    
91. STEHLE T, Grimbert P, Remy P, Moktefi A, et al
    Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression.
    Kidney Int. 2022;101:416-418.
    PubMed    
    
    
    
92. GLEESON S, Lightstone L
    BLISS-LN trial revisited: function matters.
    Kidney Int. 2022;101:224-226.
    PubMed     Abstract available
    
    
    
93. DHAUN N, McAdoo SP
    The changing role of glucocorticoids in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2022;101:201-204.
    PubMed    
    
    
    January 2022
94. KIM HJ, Jung M, Lim BJ, Han SH, et al
    New Onset of Class III Lupus Nephritis with Multi-Organ Involvement after COVID -19 Vaccination.
    Kidney Int. 2022 Jan 30. pii: S0085-2538(22)00064.
    PubMed    
    
    
    
95. LI X, Zhang X
    Comments on the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for anticoagulant therapy in patients with membranous nephropathy.
    Kidney Int. 2022;101:186-187.
    PubMed    
    
    
    
96. KLOMJIT N, Zand L
    Catastrophic kidney infarction.
    Kidney Int. 2022;101:189.
    PubMed    
    
    
    December 2021
97. ZAMBRANO S, He L, Kano T, Sun Y, et al
    Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing.
    Kidney Int. 2021 Dec 27. pii: S0085-2538(21)01211.
    PubMed     Abstract available
    
    
    
98. AYOUB I, Wolf BJ, Geng L, Song H, et al
    Prediction Models of Treatment Response in Lupus Nephritis.
    Kidney Int. 2021 Dec 3. pii: S0085-2538(21)01079.
    PubMed     Abstract available
    
    
    
99. PLAISIER E, Not A, Buob D, Ronco P, et al
    Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab.
    Kidney Int. 2021;100:1342-1344.
    PubMed    
    
    
    
100. MULLER R, Lebrun G
     Strawberry gingivitis.
     Kidney Int. 2021;100:1353.
     PubMed    
     
     
     
101. ENGHARD P, Zickler D, Sonnemann J, Schneider W, et al
     Imlifidase as novel treatment strategy in anti-neutrophil cytoplasmic antibody-induced pulmonary-renal syndrome.
     Kidney Int. 2021;100:1344-1345.
     PubMed    
     
     
     
102. DEBIEC H, Ronco P
     When contactin antibodies hit the podocyte: a new neurorenal syndrome.
     Kidney Int. 2021;100:1163-1165.
     PubMed     Abstract available
     
     
     
103. GULATI K, Edwards H, Prendecki M, Cairns TD, et al
     Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis.
     Kidney Int. 2021;100:1316-1324.
     PubMed     Abstract available
     
     
     
104. VAN GELDER T
     How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.
     Kidney Int. 2021;100:1185-1189.
     PubMed     Abstract available
     
     
     November 2021
105. KANT S, Geetha D
     Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti-neutrophil cytoplasmic antibody vasculitis.
     Kidney Int. 2021;100:1124-1127.
     PubMed    
     
     
     
106. HENDRA H, Mahalingasivam V, Salama AD, Burns A, et al
     The Case | Unexplained inflammation after treatment for granulomatosis with polyangiitis.
     Kidney Int. 2021;100:1147-1148.
     PubMed    
     
     
     October 2021
107. CAMBIER A, Gleeson PJ, Abbad L, Canesi F, et al
     SOLUBLE CD89 IS A CRITICAL FACTOR FOR MESANGIAL PROLIFERATION IN CHILDHOOD IgA NEPHROPATHY.
     Kidney Int. 2021 Oct 28. pii: S0085-2538(21)00954.
     PubMed     Abstract available
     
     
     
108. SPAIN RI, Andeen NK, Gibson PC, Samuels M, et al
     Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy.
     Kidney Int. 2021 Oct 16. pii: S0085-2538(21)00946.
     PubMed     Abstract available
     
     
     
109. MEJIA-VILET JM, Malvar A, Arazi A, Rovin BH, et al
     The Lupus Nephritis Management Renaissance.
     Kidney Int. 2021 Oct 4. pii: S0085-2538(21)00874.
     PubMed     Abstract available
     
     
     
110. VILLA M, Diaz-Crespo F, Perez de Jose A, Verdalles U, et al
     A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
     Kidney Int. 2021;100:937-938.
     PubMed    
     
     
     
111. LE QUINTREC M, Teisseyre M, Bec N, Delmont E, et al
     Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy.
     Kidney Int. 2021 Oct 1. pii: S0085-2538(21)00806.
     PubMed     Abstract available
     
     
     
112. ROVIN BH, Adler SG, Barratt J, Bridoux F, et al
     Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
     Kidney Int. 2021;100:753-779.
     PubMed     Abstract available
     
     
     
113. ROCCATELLO D, Sciascia S
     A toggle switch linking coagulation and innate immunity in antiphospholipid antibody syndrome.
     Kidney Int. 2021;100:740-742.
     PubMed    
     
     
     September 2021
114. ZAVALA-MIRANDA MF, Gonzalez-Ibarra SG, Perez-Arias AA, Uribe-Uribe NO, et al
     New onset systemic lupus erythematosus opening as class V lupus nephritis after COVID-19 vaccination.
     Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00869.
     PubMed    
     
     
     
115. ROVIN BH, Furie R, Teng YKO, Contreras G, et al
     A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
     Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00862.
     PubMed     Abstract available
     
     
     
116. HUERTA A, Caballero Bermejo AF, de Villa LF, Sedano R, et al
     Measurement of the passage of mycophenolic acid into breast milk in a patient with lupus nephritis.
     Kidney Int. 2021;100:711.
     PubMed    
     
     
     
117. SALHI S, Ribes D, Colombat M, Fortenfant F, et al
     Bortezomib plus dexamethasone for rituximab-resistant PLA2R(+) membranous nephropathy.
     Kidney Int. 2021;100:708-709.
     PubMed    
     
     
     
118. BORZA DB
     Fumarate in membranous nephropathy: more questions than answers.
     Kidney Int. 2021;100:707.
     PubMed    
     
     
     August 2021
119. GUEGUEN L, Loheac C, Saidani N, Khatchatourian L, et al
     Membranous nephropathy following anti-Covid-19 mRNA vaccination.
     Kidney Int. 2021 Aug 19. pii: S0085-2538(21)00757.
     PubMed    
     
     
     
120. TUSCHEN K, Brasen JH, Schmitz J, Vischedyk M, et al
     Relapse of Class V Lupus Nephritis after Vaccination with COVID-19 mRNA Vaccine.
     Kidney Int. 2021 Aug 2. pii: S0085-2538(21)00738.
     PubMed    
     
     
     
121. PLASSE R, Nee R, Gao S, Olson S, et al
     AKI with Gross Hematuria and IgA Nephropathy after COVID Vaccine.
     Kidney Int. 2021 Aug 2. pii: S0085-2538(21)00739.
     PubMed    
     
     
     July 2021
122. DA Y, Goh GH, Khatri P
     A Case of Membranous Nephropathy Following Pfizer-BioNTech mRNA vaccine against Coronavirus 2019.
     Kidney Int. 2021 Jul 29. pii: S0085-2538(21)00735.
     PubMed    
     
     
     
123. HANNA C, Herrera Hernandez LP, Bu L, Kizilbash S, et al
     IgA Nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine.
     Kidney Int. 2021 Jul 5. pii: S0085-2538(21)00666.
     PubMed    
     
     
     
124. RABANT M, Dessaix K, Buob D, Fagniez O, et al
     The Case | Membranous nephropathy after alemtuzumab treatment.
     Kidney Int. 2021;100:249-250.
     PubMed    
     
     
     
125. BERCHTOLD L, Letouze E, Alexander MP, Canaud G, et al
     Corrigendum to Berchtold L, Letouze E, Alexander MP, et al. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney Int. 2021;99:671-685.
     Kidney Int. 2021;100:243.
     PubMed    
     
     
     June 2021
126. KUDOSE S, Friedman P, Albajrami O, D'Agati VD, et al
     Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy.
     Kidney Int. 2021 Jun 17. pii: S0085-2538(21)00598.
     PubMed    
     
     
     
127. PERRIN P, Bassand X, Benotmane I, Bouvier N, et al
     Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy.
     Kidney Int. 2021 Jun 1. pii: S0085-2538(21)00564.
     PubMed    
     
     
     
128. NANGAKU M, Fogo AB
     Does a preclinical randomized controlled trial, pRCT, resolve the gap between animal studies and human trials?
     Kidney Int. 2021;99:1262-1264.
     PubMed     Abstract available
     
     
     May 2021
129. SEKAR A, Campbell R, Tabbara J, Rastogi P, et al
     ANCA glomerulonephritis post Moderna COVID-19 vaccination.
     Kidney Int. 2021 May 31. pii: S0085-2538(21)00555.
     PubMed    
     
     
     
130. TAN HZ, Tan RY, Jun Choo JC, Lim CC, et al
     Is COVID-19 Vaccination unmasking Glomerulonephritis?
     Kidney Int. 2021 May 22. pii: S0085-2538(21)00504.
     PubMed    
     
     
     
131. AYDIN MF, Yildiz A, Oruc A, Sezen M, et al
     Relapse of Primary Membranous Nephropathy after inactivated SARS-CoV-2 Virus Vaccination.
     Kidney Int. 2021 May 13. pii: S0085-2538(21)00494.
     PubMed    
     
     
     
132. KANO T, Suzuki H, Makita Y, Fukao Y, et al
     Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy.
     Kidney Int. 2021 May 4. pii: S0085-2538(21)00467.
     PubMed     Abstract available
     
     
     
133. CHAPMAN FA, Dhaun N
     STARMEN: progress in membranous nephropathy?
     Kidney Int. 2021;99:1242-1243.
     PubMed    
     
     
     
134. WALTHER CP
     An impending obituary for the primacy of P values in glomerulonephritis trial results?
     Kidney Int. 2021;99:1241-1242.
     PubMed    
     
     
     
135. FERNANDEZ-JUAREZ G, Rojas-Rivera J, Praga M
     The authors reply.
     Kidney Int. 2021;99:1243.
     PubMed    
     
     
     
136. ANDERS HJ, Lei Y, Rovin BH
     The authors reply.
     Kidney Int. 2021;99:1242.
     PubMed    
     
     
     April 2021
137. GUL RAHIM SE, Lin J, Wang JC
     A case of gross hematuria and IgA Nephropathy Flare up following SARS-CoV-2 vaccination.
     Kidney Int. 2021 Apr 28. pii: S0085-2538(21)00465.
     PubMed    
     
     
     
138. WHEELER DC, Toto RD, Stefansson BV, Jongs N, et al
     A pre-specified analysis of the DAPA-CKD trial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
     Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00396.
     PubMed     Abstract available
     
     
     
139. BARRATT J, Floege J
     SGLT-2 inhibition in IgA nephropathy: the new standard-of-care?
     Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00385.
     PubMed     Abstract available
     
     
     
140. LERNER GB, Virmani S, Henderson JM, Francis JM, et al
     A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy.
     Kidney Int. 2021 Apr 12. pii: S0085-2538(21)00377.
     PubMed     Abstract available
     
     
     
141. SANTORIELLO D, Bomback AS, Kudose S, Batal I, et al
     Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine.
     Kidney Int. 2021 Apr 12. pii: S0085-2538(21)00379.
     PubMed     Abstract available
     
     
     March 2021
142. FARRAH TE, Dhaun N
     Antineutrophil cytoplasm antibody positivity, kidney impairment, and cholesterol embolization.
     Kidney Int. 2021;99:774.
     PubMed    
     
     
     January 2021
143. RONCO P, Rovin B, Nangaku M, Wyatt C, et al
     Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology.
     Kidney Int. 2021;99:2-4.
     PubMed    
     
     
     
144. KUDOSE S, Santoriello D, Debiec H, Canetta PA, et al
     The clinicopathologic spectrum of segmental membranous glomerulopathy.
     Kidney Int. 2021;99:247-255.
     PubMed     Abstract available
     
     
     November 2020
145. TURNER MP, Storey BC, Mittal S, Macanovic J, et al
     Candida crescents in a renal allograft.
     Kidney Int. 2020;98:1356.
     PubMed    
     
     
     September 2020
146. SCHENA FP, Anelli VW, Trotta J, Di Noia T, et al
     Development and testing of an artificial intelligence tool for predicting end stage kidney disease in patients with immunoglobulin A nephropathy.
     Kidney Int. 2020 Sep 1. pii: S0085-2538(20)30969.
     PubMed     Abstract available
     
     
     April 2020
147. VAN BOMMEL EJM, Lytvyn Y, Perkins BA, Soleymanlou N, et al
     Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
     Kidney Int. 2020;97:631-635.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.